Shenzhen Accord Pharmaceutical Co., Ltd. The Third Quarterly Report for 2009(Full Text)
1
Shenzhen Accord Pharmaceutical Co., Ltd.
The Third Quarterly Report for 2009
(Full Text)
§1. Important Notes
1.1 Board of Directors and the Supervisory Committee of Shenzhen Accord Pharmaceutical Co.,
Ltd. (hereinafter referred to as the Company) and its directors, supervisors and senior executives
hereby confirm that there are no any fictitious statements, misleading statements, or important
omissions carried in this report, and shall take all responsibilities, individual and/or joint, for the
reality, accuracy and completion of the whole contents.
1.2 The Third Quarterly Financial Report of 2009 has not been audited by CPAs.
1.3 Chairman of the Board Mr. Shi Jinming, General Manager Mr. Yan Zhigang, CFO Mr. Wei
Pingxiao and Financial Manager Mr. Chi Guoguang hereby confirm that the Financial Report of the
Third Quarterly Report is true and complete.
§2. Company Profile
2.1 Main accounting highlights and financial indexes:
Unit: RMB
Sep. 30, 2009 Dec. 31, 2008 Increase/decrease scope
(%)
Total assets (RMB) 5,012,704,506.58 3,923,236,768.25 27.77%
Owners’ equities attributable to the
shareholders of listed company
(RMB)
783,305,066.11 658,006,016.89 19.04%
Share capital (Share) 288,149,400.00 288,149,400.00 0.00%
Net assets per share attributable to
the shareholders of listed company
(RMB/Share)
2.718 2.284 19.00%
July-Sep. 2009
Increase/decrease
over the same
period of the last
year (%)
Jan.-Sep. 2009
Increase/decrease
over the same
period of the last
year (%)
Total operating income (RMB) 2,941,569,733.45 27.72% 7,980,050,403.66 24.95%
Net profit attributable to the
shareholders of listed company
(RMB)
47,257,233.24 5.29% 146,041,128.28 17.99%
Net cash flow arising from operating
activities (RMB) - - 194,251,374.04 14.87%
Net cash flow arising from operating
activities per share (RMB/Share) - - 0.674 14.87%
Basic earnings per share
(RMB/Share) 0.164 5.13% 0.507 17.91%
Diluted earnings per share
(RMB/Share) 0.164 5.13% 0.507 17.91%
Return on equity (%) 6.03% -1.04% 18.64% -0.85%
Return on equity after deducting
non-recurring gains and losses (%) 5.72% -0.48% 16.54% -0.50%Shenzhen Accord Pharmaceutical Co., Ltd. The Third Quarterly Report for 2009(Full Text)
2
Unit: RMB
2.2 Total number of shareholders at the end of the report period and shares held by the top ten
shareholders with unrestricted conditions
Unit: Share
Items of non-recurring gains and losses Amount from year begin to
the end of report period Remarks
Gains and losses from the disposal of non-current asset 13,772,974.57
Including disposed the
equity income of
retails such as
Guangdong Accord
Drugstore Co., Ltd.
and Guangxi Accord
Drugstore Chains Co.,
Ltd.
Governmental subsidy calculated into current gains and
losses, while closely related with the business of the
Company, excluding the fixed-amount or fixed-proportion
governmental subsidy according to the unified national
standard
1,126,000.00
Current net gains/losses of subsidiaries from period-begin to
consolidated date occurred by enterprise merger under the
same control
2,483,497.55
Net profit as of Jan.-
June from purchasing
enterprise--Sinopharm
Medicine Holding
Nanning Co., Ltd.
under the same control
Other non-operating income and expense excluded the
aforementioned business 3,775,072.52
Influenced amount of minority shareholders’ gains/losses -2,368,159.20
Impact on income tax -2,315,593.49
Total 16,473,791.95 -
Total number of shareholders
at the end of report period 15,112
Particulars about the shares held by the top ten shareholders with unrestricted conditions
Full Name of shareholder Unrestricted shares held Type of shares
SINOPHARM MEDICINE HOLDING CO.,
LTD. 110,459,748 RMB common share
BANK OF CHINA － HARVEST THEME
SELECTED MIXED FUND 9,648,454 RMB common share
AGRICULTURAL BANK OF CHINA －
GREATWALL ANXIN RETURN MIXED
FUND
7,721,844 RMB common share
BANK OF CHINA － FRANKLIN
TEMPLETON SEALAND POTENTIAL
COMBINATION FUND
7,050,317 RMB common share
PING AN INSURANCE (GROUP) COMPANY
OF CHINA, LTD. －TRADITION－GENERAL
INSURANCE PRODUCTS
6,112,804 RMB common share
BANK OF CHINA － HARVEST RESEARCH
SELECTED STOCK FUND 5,400,000 RMB common share
CHINA INDUSTRIAL AND COMMERCIAL B 4,963,365 RMB common shareShenzhen Accord Pharmaceutical Co., Ltd. The Third Quarterly Report for 2009(Full Text)
3
§3. Significant events
3.1 Particulars about material changes in items of main accounting statement and financial index,
and explanations of reasons
√Applicable □Inapplicable
ANK－BOSHI SELECTIVE STOCK FUND
AGRICULTURAL BANK OF CHINA －
FRANKLIN TEMPLETON SEALAND FLEX
CAP FUND
4,949,136 RMB common share
CHINA INDUSTRIAL AND COMMERCIAL
BANK－GUANGFA JUFENG STOCK FUND 4,670,215 RMB common share
BANK OF COMMUNICATIONS － HUAAN
STRATEGIC SELECTED STOCK FUND 3,500,000 RMB common share
1. Account receivable: the amount for period-end was RMB 2,505.14 million, 33.87% up over that of
year-begin. Main reasons accounting for the growth: at one side, the effect of integrated operation
integrating Guangdong and Guangxi provinces began to show up, because expansion of sale scale
resulted in increase of accounts receivable; at another side, purchasing the subsidiary-Zhijun
Wanqing also made the Company increase accounts receivable at period-end over that of year-begin.
2. Account paid in advance: the amount for period-end was RMB 65.81 million, 52.54% up over that
of year-begin. Main reason accounting for the growth: purchasing the subsidiary-Zhijun Wanqing
also made the Company increase accounts paid in advance at period-end over that of year-begin.
3. Other receivable: the amount for period-end was RMB 37.07 million, 32.24% down over that of
year-begin. Main reason accounting for the decline: Sinopharm Nanning, the subsidiary of the
Company, collected back the current money totaling to RMB 20.08 million from Nanning Medicine
Wholesale Station in 2009.
4. Investment real estate: the amount for period-end was RMB 38.31 million, 67.68% up over that of
year-begin. Main reason accounting for the growth: the Company and its underlying subsidiaries-
Jianmin Medicine and Zhijun Pharmaceuticals increased house properties available for external lease.
5. Construction in process: the amount for period-end was RMB 30.24 million, 61.12% up over that
of year-begin. Main reason accounting for the growth: account was input by Zhijun Pharmaceuticals
for newly constructing workshop producing cephalo solid; expenditure was made by Zhijun Wanqing
to reconstruct the old buildings.
6. Intangible assets: the amount for period-end was RMB 98.48 million, 70.95% up over that of yearbegin.
Main reason accounting for the growth: that the Company purchased its subsidiary-Zhijun
Wanqing resulted in increase of intangible assets at period-end over that of year-begin.
7. Long-term deferred expense: the amount for period-end was RMB 10.1 million, 40.82% down over
that of year-begin. Main reason accounting for the decline: the Company and its subsidiary-
Sinopharm Liuzhou transferred 4 retailers.
8. Short-term loans: the amount for period-end was RMB 848.91 million, 115.65% up over that of
year-begin. Main reason accounting for the growth: line of credit permitted by bank was increased to
support business development which had requirement for capital input in some degree; meanwhile,
expansion of sale scale brought in increase of discount of notes.
9. Account payable: the amount for period-end was RMB 1,958.67 million, 36.70% up over that of
year-begin. Main reason accounting for the growth: the good growth tendency of sales drove increase
of purchase.
10. Account received in advance: the amount for period-end was RMB 29.45 million, 56.88% up overShenzhen Accord Pharmaceutical Co., Ltd. The Third Quarterly Report for 2009(Full Text)
4
that of year-begin. Main reason accounting for the growth: increase of sales brought along increase of
account paid in advance.
11. Tax payable: the amount for period-end was RMB 32.52 million, 115.07% up over that of yearbegin.
Main reason accounting for the growth: the great rising sales income correspondingly brought
increase of VAT payable.
12. Dividend payable: the amount for period-end was RMB 2 million, 69.91% down over that of
year-begin. Main reason accounting for the decline: at period-begin, the Company owed dividend
worth of RMB 3.75 million to China Medicine Group Shanghai Company, the original minor
shareholder of Sinopharm Guangzhou; Sinopharm Nanning-the subsidiary of the Company, owed
dividend worth of RMB 2.9 million to Sinopharm Holdings Co., Ltd. and Sinopharm Group
Medicine Holding (Shanghai) Co., Ltd. The two dividends were all paid in this report period.
13. Other payable: the amount for period-end was RMB 195.61 million, 36.58% down over that of
year-begin. Main reason accounting for the decline: the loan totaling to RMB 60 million that the
Company owed to Sinopharm Holdings and the account of RMB 15.33 million that the Company
owed to China Medicine Group (Shanghai) Co., Ltd. arising from purchasing 10% equities of
Sinopharm Guangzhou were included in the amount for period-begin, and in this report period, the
two accounts were paid off; besides, through selling the retailing equities of Guangdong Accord, the
Company brought down other payable with RMB 12.74 million at period-end over that of year-begin.
14. Non-current liability due within one year: the amount for period-end was RMB 0, 100% down
over that of year-begin. Main reason accounting for the decline: the long-term loan provided by
Anlian Branch of China Merchants Bank for the Company’s subsidiary-Zhijun Pharmaceuticals at
period-begin was due within one year, and had turned to be short-term loan in this report period.
15. Long-term loan: the amount for period-end was RMB 60 million, 100% up over that of year-begin.
Main reason accounting for the growth: the Company’s subsidiary-Zhijun Pharmaceuticals newly
applied for long-term loan totaling to RMB 30 million from Anlian Branch of China Merchants Bank
in this report period.
16. Special payable: the amount for period-end was RMB 1.24 million, 54.38% up over that of yearbegin.
Main reason accounting for the growth: the Company’s subsidiary-Zhijun Pharmaceuticals
obtained encouragement account for industry technical progress as expense used for developing ERP
system.
17. Deferred income tax liabilities: the amount for period-end was RMB 17.52 million, 43.94% up
over that of year-begin. Main reason accounting for the growth: because the Company adopted fair
value statement when consolidating Zhijun Wanqing, temporary balance existed between its taxing
base and fair value of various identifiable assets and liabilities.
18. Capital reserve: the amount for period-end was RMB 5.03 million, 85.44% down over that of
year-begin. Main reason accounting for the decline: as the Company purchased Sinopharm Nanningthe
subsidiary under the same control, accountings were made according to relevant regulations of
Accounting Standards for Enterprise No. 20-Enterprise Merger.
19. Undistributed profit: the amount for period-end was RMB 480.82 million, 47.70% up over that of
year-begin.Main reasons accounting for the growth:
(1)Net profit attributable to parent company totaling to RMB 146.04 million was made in this report
period.
(2)In this report period, the Company transferred 100% equities of GuangdongAccord Drug Store Co.,
Ltd. whose wholly-owned subsidiaries-Shenzhen Accord Medicine Chain Co., Ltd. and Guangzhou
Accord Drug Store Chain Co., Ltd. were in series losses. The unconfirmed investment loss occurred
before Dec. 31st of 2006 was directly written into owners’ gains and losses, totaling to RMB 39.66
million.
(3)Profit Distribution scheme for 2008 was discussed and approved in the 2008 Shareholders’ GeneralShenzhen Accord Pharmaceutical Co., Ltd. The Third Quarterly Report for 2009(Full Text)
5
Meeting of the Company held on Apr. 13th of 2009. Dividend totaling to RMB 28.82 million was
cashed in this report period.
20. Minor shareholders’ equity: the amount for period-end was RMB 53.19 million, 148.73% up over
that of year-begin.Main reason accounting for the growth: Purchasing 75% equities of its subsidiary-
ZhijunWanqing, the Company brought along increase in minor shareholders’ equity.
21. Operating tax and extras in this period was RMB 10.04 million, which increased 46.70%
compared with that in the same period of last year. The main reason was that: the business scale of
the Company enlarged and tax increased.
22. The assets impairment losses in this period were RMB 3.57 million, which increased 283.19%
compared with that in the same period of last year. The main reason was that: the impairment
provision of account receivable withdrawal in this period increased.
23. The investment income in this period was RMB 28.18 million, which increased 154.49%
compared with that in the same period of last year. The main reason was that: on the one hand, the
affiliated company –Shenzhen Main Luck Pharmaceuticals INC had good operation performance,
which caused the increase of investment income; on the other hand, the Company transferred equities
of Guangdong Accord Drugstore Co., Ltd. and Guangxi Accord Drugstore Chains Co., Ltd. and gained
good investment income.
24. Non-operating income in this period was RMB 7.02 million, which decreased 56.28% compared
with that in the same period of last year. The main reason was that: the subsidiary company
–Shenzhen Zhijun Pharmaceutical Co., Ltd. gained government subsidy including scientific research
outlay and had good income from selling old real estate in the same period of last year.
25. Income tax in this period was RMB 47.72 million, which increased 59.06% compared with that in
the same period of last year. The main reason was that: on the one hand, the profit level was raised
which caused increase of income tax; on the other hand, selling retail equity and internal transferring
equity caused increase of income tax.
26. Minority shareholders’ gains and losses in this period was RMB 4.47 million, which decreased
41.37% compared with that in the same period of last year. The main reason was that: China National
Pharmaceutical Group Shanghai Company held 10% equities of the subsidiary of the Company
–Sinopharm Medicine Holding Guangzhou Co., Ltd.
27. Other cash received concerning operating activities in this period was RMB 125.36 million, which
increased 33.74% compared with that in the same period of last year. The main reason was that: on the
one hand, the sales scale of the Company enlarged, which caused the increase of Other cash received
concerning operating activities; on the other hand, the purchased subsidiary company – Zhijun
Wanqing also had some influence on it.
28. The taxes paid in this period were RMB 161.3 million, which increased 31.48% compared with
that in the same period of last year. The main reason was that: on the one hand, the sales scale of the
Company enlarged and the profit level was raised, which caused the increase of taxes; on the other
hand, the purchased subsidiary company – ZhijunWanqing also had some influence on it.
29. The cash received from investment income in this period was RMB 3,600, which decreased
99.92% compared with that in the same period of last year. The main reason was that: the affiliated
enterprise –Shenzhen Main Luck Pharmaceuticals INC did not distribute dividends in this period.
30. Net cash received from disposal of fixed, intangible and other long-term assets in this period was
RMB 5.48 million, which decreased 44.90% compared with that in the same period of last year. The
main reason was that: the subsidiary company –Shenzhen Zhijun Pharmaceutical Co., Ltd. removed
its factory and disposed old assets in the same period of last year.
31. Net cash received from disposal of subsidiaries and other units in this period was RMB 59.96
million, which increased 100% compared with that in the same period of last year. The main reason
was that: the Company received payment of transferring equity in this period.
32. Cash paid for investment in this period was RMB 0, which decreased RMB 15.33 million with the
decrease rate of 100% compared with that in the same period of last year. The main reason was that: tShenzhen Accord Pharmaceutical Co., Ltd. The Third Quarterly Report for 2009(Full Text)
6
3.2 Progress of significant events, their influences, and analysis and explanation of their solutions
□Applicable √Inapplicable
3.3 Implementations of commitments by the Company, shareholders and actual controller
□Applicable √Inapplicable
3.4 Estimation of accumulative net profit from the beginning of the year to the end of next report
period to be loss probably or the warning of its material change compared with the corresponding
period of the last year and explanation of reason
□Applicable √Inapplicable
3.5 Particulars about the other significant events which needed explanations
3.5.1 Activities on receiving research, communication and interview in the report period
In the report period, there were no receiving spot research, communication and written inquiry from
the investors.
3.6 Particulars about derivatives investment
□Applicable √Inapplicable
he Company paid the account of purchasing 10% equity of subsidiary company - Sinopharm
Medicine Holding Guangzhou Co., Ltd. in the same period of last year.
33. Net cash paid by the subsidiaries and other units in this period was RMB 105.63 million, which
increased 2,012.59% compared with that in the same period of last year. The main reason was that:
the Company paid the account of purchasing 75% equities of Zhijun Wanqing and 100% equities of
Dongguan Accord in this period.
34. Cash received from the loans in this period was RMB 601.45 million, which increased 59.16%
compared with that in the same period of last year. The main reason was that: the Company and
underlying subsidiaries increased bank line of credit to support business development.
35. Other cash received concerning operating activities in this period was RMB 222.56 million,
which increased 160.69% compared with that in the same period of last year. The main reason was
that: the Company received loan from Sinopharm and Sinopharm increased special capital for
earthquake disaster relief.
36. Cash paid for dividend and profit distributing or interest paying in this period was RMB 66.21
million, which increased 108.56% compared with that in the same period of last year. The main
reason was that: the Company distributed cash dividends of RMB 28.82 million in this period; the
subsidiary company – Sinopharm Liuzhou paid dividends of RMB 4.9 million to minority
shareholders.
37. Other cash paid concerning financing activities in this period was RMB 365.44 million, which
increased 2,419.38% compared with that in the same period of last year. The main reason was that:
the loan that the Company paid back to Sinopharm increased.
On June 19, 2009, the Company purchased the enterprise Sinopharm Medicine Holding Nanning Co.,
Ltd. under the same control, in accordance with the regulations of Accounting Standard for Business
Enterprises No. 20 - Business Combinations, the Company made adjustments on comparative
statements as of Sep. 2008. The retroactive adjustments included that to increase the total profit and
net profit attributable to owners of parent company from Jan. to Sep. of 2008 both with the amount of
RMB 2,984,014.58, and also to increase the equities attributable to owners of parent company and
total assets at the end of Sep. of year 2008 both with the amount of RMB 29,954,560.70.Shenzhen Accord Pharmaceutical Co., Ltd. The Third Quarterly Report for 2009(Full Text)
7
3.6.1 Particulars about the positions of derivatives investment at the end of report period
□Applicable √Inapplicable
§4. Appendix
4.1 Balance sheet
Prepared by Shenzhen Accord Pharmaceutical Co., Ltd. Sep. 30, 2009 Unit: RMB
Items Balance at period-end Balance at year-begin
Consolidation Parent Company Consolidation Parent Company
Current assets:
Monetary funds 459,477,701.64 108,603,186.61 381,663,418.93 62,369,583.65
Settlement provisions
Capital lent
Transaction finance
asset
Notes receivable 233,922,206.31 5,353,557.80 213,830,030.45 254,500.00
Accounts receivable 2,505,138,257.78 315,581,400.64 1,871,252,754.52 243,301,803.10
Accounts paid in
advance 65,811,460.98 5,851,313.64 43,142,735.93 4,919,683.46
Insurance receivable
Reinsurance receivables
Contract reserve of
reinsurance receivable
Interest receivable
Dividend receivable
Other receivables 37,066,289.76 510,404,927.49 54,701,481.63 242,415,823.08
Purchase restituted
finance asset
Inventories 952,126,620.00 109,009,704.76 752,146,181.21 94,249,578.90
Non-current asset due
within one year
Other current assets
Total current assets 4,253,542,536.47 1,054,804,090.94 3,316,736,602.67 647,510,972.19
Non-current assets:
Granted loans and
advances
Finance asset available
for sales
Held-to-maturity
investment
Long-term account
receivable
Long-term equity
investment 81,646,339.88 648,542,708.24 69,578,981.80 323,756,562.92
Investment property 38,311,405.70 7,793,564.98 22,848,031.69 2,140,353.75
Fixed assets 414,143,772.22 28,610,334.42 376,881,334.49 36,732,350.96
Construction in progress 30,236,762.63 253,886.24 18,766,355.77 253,886.24
Engineering materialShenzhen Accord Pharmaceutical Co., Ltd. The Third Quarterly Report for 2009(Full Text)
8
Disposal of fixed asset 345,230.59
Productive biological
asset
Oil and gas asset
Intangible assets 98,479,037.87 29,897,007.38 57,607,282.99 30,622,772.31
Expense on Research
and Development 235,375.01
Goodwill 39,668,174.87
Long-term expenses to
be apportioned 10,097,192.61 105,614.15 17,061,272.11 276,057.82
Deferred income tax
asset 8,909,241.15 10,716,504.87
Other non-current asset 37,089,437.58 33,040,401.86
Total non-current asset 759,161,970.11 715,203,115.41 606,500,165.58 393,781,984.00
Total assets 5,012,704,506.58 1,770,007,206.35 3,923,236,768.25 1,041,292,956.19
Current liabilities:
Short-term loans 848,909,407.55 389,346,020.94 393,660,380.07 80,171,729.25
Loan from central bank
Absorbing deposit and
interbank deposit
Capital borrowed
Transaction financial
liabilities
Notes payable 907,502,311.66 143,981,976.96 838,537,721.27 129,298,292.87
Accounts payable 1,958,667,182.92 328,239,815.80 1,432,873,603.58 268,335,731.42
Accounts received in
advance 29,449,996.30 6,936,576.68 18,771,893.29 4,626,342.73
Selling financial asset of
repurchase
Commission charge and
commission payable
Wage payable 77,911,440.12 18,057,013.80 86,764,697.85 14,678,407.64
Taxes payable 32,521,348.85 994,720.93 15,121,308.90 -963,780.92
Interest payable 236,469.51 742,393.70 39,700.00
Dividend payable 2,000,000.00 6,646,096.98
Other accounts payable 195,606,406.81 327,097,121.10 308,422,007.24 119,209,791.88
Reinsurance payables
Insurance contract
reserve
Security trading of
agency
Security sales of agency
Non-current liabilities
due within 1 year 57,720,000.00
Other current liabilities
Total current liabilities 4,052,804,563.72 1,214,653,246.21 3,159,260,102.88 615,396,214.87
Non-current liabilities:
Long-term loans 60,000,000.00 30,000,000.00Shenzhen Accord Pharmaceutical Co., Ltd. The Third Quarterly Report for 2009(Full Text)
9
4.2 Profit statement in the report period
Prepared by Shenzhen Accord Pharmaceutical Co., Ltd. July-Sep. 2009 Unit: RMB
Bonds payable
Long-term account
payable 47,329.80 51,261.00
Special accounts
payable 1,235,000.00 800,000.00 800,000.00 800,000.00
Projected liabilities
Deferred income tax
liabilities 17,523,546.32 12,174,180.87
Other non-current
liabilities 44,602,343.31 41,561,743.31
Total non-current liabilities 123,408,219.43 800,000.00 84,587,185.18 800,000.00
Total liabilities 4,176,212,783.15 1,215,453,246.21 3,243,847,288.06 616,196,214.87
Owner’s equity (or
shareholders’ equity):
Paid-in capital (or share
capital) 288,149,400.00 288,149,400.00 288,149,400.00 288,149,400.00
Capital public reserve 5,030,338.57 2,508,769.94 34,555,838.57 2,508,769.94
Less: Inventory shares
Reasonable reserve
Surplus public reserve 9,303,064.31 9,761,340.26 12,781,301.82
Provision of general risk
Retained profit 480,822,263.23 263,895,790.20 325,539,438.06 121,657,269.56
Balance difference of
foreign currency translation
Total owner’s equity
attributable to parent
company
783,305,066.11 554,553,960.14 658,006,016.89 425,096,741.32
Minority interests 53,186,657.32 21,383,463.30
Total owner’s equity 836,491,723.43 554,553,960.14 679,389,480.19 425,096,741.32
Total liabilities and owner’s
equity 5,012,704,506.58 1,770,007,206.35 3,923,236,768.25 1,041,292,956.19
Items This period The same period of last year
Consolidation Parent Company Consolidation Parent Company
I. Total operating income 2,941,569,733.45 467,728,309.42 2,303,099,254.06 370,371,196.21
Including: Operating income 2,941,569,733.45 467,728,309.42 2,303,099,254.06 370,371,196.21
Interest income
Insurance gained
Commission charge and
commission income
II. Total operating cost 2,890,320,255.02 477,006,769.22 2,255,951,614.70 370,766,632.15
Including: Operating cost 2,712,354,268.70 446,402,131.77 2,097,944,291.68 353,086,535.46
Interest expense
Commission charge and
commission expense
Cash surrender valueShenzhen Accord Pharmaceutical Co., Ltd. The Third Quarterly Report for 2009(Full Text)
10
Net amount of expense
of compensation
Net amount of
withdrawal of insurance
contract reserve
Bonus expense of
guarantee slip
Reinsurance expense
Operating tax and extras 4,057,000.33 190,521.36 2,401,463.69 159,952.65
Sales expenses 89,974,563.91 13,589,463.90 84,932,098.12 9,133,698.14
Administration expenses 73,839,778.99 17,109,719.55 55,954,038.42 9,322,855.61
Financial expenses 11,970,901.86 529,192.74 12,603,145.61 -551,274.07
Losses of devaluation of
asset -1,876,258.77 -814,260.10 2,116,577.18 -385,135.64
Add: Changing income
of fair value(Loss is listed
with “-”)
Investment income (Loss
is listed with “-”) 5,429,118.58 5,519,440.86 4,443,455.94 -522,839.61
Including: Investment
income on affiliated company
and joint venture
5,401,918.58 6,054,926.30 4,350,660.33 -522,839.61
Exchange income (Loss
is listed with “-”)
III. Operating profit (Loss is
listed with “-”) 56,678,597.01 -3,759,018.94 51,591,095.30 -918,275.55
Add: Non-operating
income 4,759,234.61 36,285.78 5,897,021.02 -904.43
Less: Non-operating
expense 620,984.43 127,521.33 298,766.09 22,314.84
Including: Disposal loss
of non-current asset 298,873.13 6,822.32 6,279.81
IV. Total Profit (Loss is
listed with “-”) 60,816,847.19 -3,850,254.49 57,189,350.23 -941,494.82
Less: Income tax
expense 13,695,178.54 0.00 10,037,511.78 0.00
V. Net profit (Net loss is listed
with “-”) 47,121,668.65 -3,850,254.49 47,151,838.45 -941,494.82
Net profit attributable to
owner’s of parent company 47,257,233.24 44,881,722.00
Minority shareholders’
gains and losses -135,564.59 2,270,116.45
VI. Earnings per share
i. Basic earnings per share 0.164 0.156
ii. Diluted earnings per share 0.164 0.156
VII. Other consolidated
income 0.00 0.00 0.00 0.00
VIII. Total consolidated
income 47,121,668.65 -3,850,254.49 47,151,838.45 -941,494.82
Total consolidated income
attributable to owners of
parent company
47,257,233.24 -3,850,254.49 44,881,722.00 -941,494.82
Total consolidated income attr -135,564.59 2,270,116.45Shenzhen Accord Pharmaceutical Co., Ltd. The Third Quarterly Report for 2009(Full Text)
11
4.3 Profit statement from year-begin to the end of report period
Prepared by Shenzhen Accord Pharmaceutical Co., Ltd. Jan.-Sep. 2009 Unit: RMB
ibutable to minority
shareholders
Items Amount in this period Amount in last period
Consolidation Parent Company Consolidation Parent Company
I. Total operating income 7,980,050,403.66 1,225,195,086.08 6,386,831,502.85 1,023,791,986.76
Including: Operating income 7,980,050,403.66 1,225,195,086.08 6,386,831,502.85 1,023,791,986.76
Interest income
Insurance gained
Commission charge and
commission income
II. Total operating cost 7,816,161,735.87 1,239,315,003.21 6,251,573,903.95 1,028,488,777.16
Including: Operating cost 7,315,862,811.08 1,165,229,619.38 5,819,458,757.89 971,580,358.70
Interest expense
Commission charge and
commission expense
Cash surrender value
Net amount of expense of
compensation
Net amount of withdrawal
of insurance contract reserve
Bonus expense of
guarantee slip
Reinsurance expense
Operating tax and extras 10,043,792.54 625,947.30 6,846,607.32 369,484.15
Sales expenses 269,470,926.25 36,018,165.82 221,560,424.63 28,082,362.89
Administration expenses 184,279,042.10 36,337,439.66 164,853,795.70 29,210,613.53
Financial expenses 32,939,041.26 1,145,166.39 40,801,032.05 243,813.59
Losses of devaluation of
asset 3,566,122.64 -41,335.34 -1,946,713.64 -997,855.70
Add: Changing income of
fair value(Loss is listed with
“-”)
Investment income (Loss
is listed with “-”) 28,184,939.50 201,354,432.16 11,074,942.97 64,597,830.49
Including: Investment
income on affiliated company
and joint venture
13,962,258.08 8,988,411.39 10,982,146.36 -121,884.46
Exchange income (Loss is
listed with “-”)
III. Operating profit (Loss is
listed with “-”) 192,073,607.29 187,234,515.03 146,332,541.87 59,901,040.09
Add: Non-operating
income 7,021,260.69 61,658.77 16,060,626.48 2,943,168.97
Less: Non-operating
expense 868,008.15 144,218.18 997,352.16 35,804.25
Including: Disposal loss
of non-current asset 477,000.49 6,568.35 120,002.55 19,769.22Shenzhen Accord Pharmaceutical Co., Ltd. The Third Quarterly Report for 2009(Full Text)
12
4.4 Cash flow statement from year-begin to the end of report period
Prepared by Shenzhen Accord Pharmaceutical Co., Ltd. Jan.-Sep. 2009 Unit: RMB
IV. Total Profit (Loss is listed
with “-”) 198,226,859.83 187,151,955.62 161,395,816.19 62,808,404.81
Less: Income tax expense 47,718,003.48 30,000,007.15
V. Net profit (Net loss is listed
with “-”) 150,508,856.35 187,151,955.62 131,395,809.04 62,808,404.81
Net profit attributable to
owner’s of parent company 146,041,128.28 123,776,036.37
Minority shareholders’
gains and losses 4,467,728.07 7,619,772.67
VI. Earnings per share
i. Basic earnings per share 0.507 0.430
ii. Diluted earnings per share 0.507 0.430
VII. Other consolidated
income 39,664,537.80 0.00 0.00 0.00
VIII. Total consolidated
income 190,173,394.15 187,151,955.62 131,395,809.04 62,808,404.81
Total consolidated income
attributable to owners of parent
company
185,705,666.08 187,151,955.62 123,776,036.37 62,808,404.81
Total consolidated income
attributable to minority
shareholders
4,467,728.07 7,619,772.67
Items Amount in this period Amount in last period
Consolidation Parent Company Consolidation Parent Company
I. Cash flows arising from
operating activities:
Cash received from
selling commodities and
providing labor services
7,977,047,905.46 1,360,053,725.45 6,257,631,364.50 1,094,671,846.63
Net increase of customer
deposit and interbank deposit
Net increase of loan from
central bank
Net increase of capital
borrowed from other financial
institution
Cash received from
original insurance contract fee
Net cash received from
reinsurance business
Net increase of insured
savings and investment
Net increase of disposal
of transaction financial asset
Cash received from interest,
commission charge and
commission
Net increase of capital
borrowed
Net increase of returned bShenzhen Accord Pharmaceutical Co., Ltd. The Third Quarterly Report for 2009(Full Text)
13
usiness capital
Write-back of tax
received 474,228.60 1,064,393.78 158,445.78
Other cash received
concerning operating activities 125,357,181.73 15,311,811.92 93,733,884.42 15,095,244.53
Subtotal of cash inflow
arising from operating
activities
8,102,879,315.79 1,375,365,537.37 6,352,429,642.70 1,109,925,536.94
Cash paid for purchasing
commodities and receiving
labor service
7,185,564,042.27 1,168,997,713.26 5,577,916,510.20 999,728,338.07
Net increase of customer
loans and advances
Net increase of deposits
in central bank and interbank
Cash paid for original
insurance contract
compensation
Cash paid for interest,
commission charge and
commission
Cash paid for bonus of
guarantee slip
Cash paid to/for staff and
workers 246,701,716.47 24,910,442.20 225,248,918.36 29,704,070.40
Taxes paid 161,301,290.34 15,967,727.50 122,683,060.35 10,618,326.53
Other cash paid
concerning operating activities 315,060,892.67 35,501,413.54 257,479,266.01 37,336,498.43
Subtotal of cash outflow
arising from operating
activities
7,908,627,941.75 1,245,377,296.50 6,183,327,754.92 1,077,387,233.43
Net cash flows arising
from operating activities 194,251,374.04 129,988,240.87 169,101,887.78 32,538,303.51
II. Cash flows arising from
investing activities:
Cash received from
recovering investment
Cash received from
investment income 3,618.16 77,532,274.50 4,534,232.28 111,580,624.49
Net cash received from
disposal of fixed, intangible
and other long-term assets
5,479,195.98 5,243,565.12 9,944,652.63 9,100.00
Net cash received from
disposal of subsidiaries and
other units
59,957,664.50 65,613,100.00
Other cash received
concerning investing activities
Subtotal of cash inflow
from investing activities 65,440,478.64 148,388,939.62 14,478,884.91 111,589,724.49
Cash paid for purchasing
fixed, intangible and other
long-term assets
69,151,624.75 2,598,675.87 72,856,821.63 1,338,240.00
Cash paid for investment 15,330,550.00 15,330,550.00
Net increase of mortgaged
loans
Net cash received from su 105,629,510.42 171,581,650.00 5,000,000.00 5,002,978.49Shenzhen Accord Pharmaceutical Co., Ltd. The Third Quarterly Report for 2009(Full Text)
14
4.5 Auditor’s report
Auditor’s opinions: Un-audited
bsidiaries and other units
Other cash paid
concerning investing activities 2,067,342.50 17,877,392.31
Subtotal of cash outflow
from investing activities 176,848,477.67 192,057,718.18 93,187,371.63 21,671,768.49
Net cash flows arising
from investing activities -111,407,999.03 -43,668,778.56 -78,708,486.72 89,917,956.00
III. Cash flows arising from
financing activities
Cash received from
absorbing investment
Including: Cash received
from absorbing minority
shareholders’ investment by
subsidiaries
Cash received from loans 601,449,691.57 310,000,000.00 377,894,752.00 125,000,000.00
Cash received from
issuing bonds
Other cash received
concerning financing activities 222,557,942.67 798,282,567.20 85,371,242.64 214,954,113.01
Subtotal of cash inflow
from financing activities 824,007,634.24 1,108,282,567.20 463,265,994.64 339,954,113.01
Cash paid for settling
debts 397,381,770.26 90,000,000.00 370,000,000.00 125,000,000.00
Cash paid for dividend
and profit distributing or
interest paying
66,214,037.21 33,664,641.61 31,747,776.27 2,233,014.09
Including: Dividend and
profit of minority shareholder
paid by subsidiaries
4,900,000.00 0.00
Other cash paid
concerning financing activities 365,440,872.21 1,024,703,784.94 14,505,172.13 294,869,408.49
Subtotal of cash outflow
from financing activities 829,036,679.68 1,148,368,426.55 416,252,948.40 422,102,422.58
Net cash flows arising
from financing activities -5,029,045.44 -40,085,859.35 47,013,046.24 -82,148,309.57
IV. Influence on cash and cash
equivalents due to fluctuation
in exchange rate
-46.86 -119.34 -119.34
V. Net increase of cash and
cash equivalents 77,814,282.71 46,233,602.96 137,406,327.96 40,307,830.60
Add: Balance of cash and
cash equivalents at the period -
begin
381,663,418.93 62,369,583.65 279,912,364.29 54,841,676.10
VI. Balance of cash and cash
equivalents at the period -end 459,477,701.64 108,603,186.61 417,318,692.25 95,149,506.70
